Goldman Sachs Group set a €65.00 ($75.58) price objective on Gerresheimer (ETR:GXI) in a report published on Thursday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
GXI has been the subject of a number of other reports. Credit Suisse Group set a €87.00 ($101.16) price target on Gerresheimer and gave the company a buy rating in a research report on Wednesday. HSBC set a €85.00 ($98.84) price target on Gerresheimer and gave the company a buy rating in a research report on Wednesday, September 11th. Independent Research set a €80.00 ($93.02) price target on Gerresheimer and gave the company a neutral rating in a research report on Monday, July 15th. Hauck & Aufhaeuser set a €50.00 ($58.14) price target on Gerresheimer and gave the company a sell rating in a research report on Friday, July 12th. Finally, Berenberg Bank set a €81.00 ($94.19) price target on Gerresheimer and gave the company a buy rating in a research report on Friday, October 4th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. Gerresheimer presently has a consensus rating of Hold and a consensus target price of €72.16 ($83.90).
GXI stock opened at €64.35 ($74.83) on Thursday. The company has a debt-to-equity ratio of 64.56, a current ratio of 0.85 and a quick ratio of 0.56. The business has a 50 day simple moving average of €66.93 and a 200-day simple moving average of €67.48. The firm has a market capitalization of $2.02 billion and a PE ratio of 9.76. Gerresheimer has a 1 year low of €51.10 ($59.42) and a 1 year high of €74.80 ($86.98).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.